Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review
Abstract Background: After introducing Covid‐19 vaccines, a few side effects were reported, pityriasis rosea being one of them. Therefore, this study will systematically review its manifestation afteradministration.Methods: Databases were searched, covering a timeline from December 1, 2019 to Februa...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Immunity, Inflammation and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/iid3.804 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849732027962621952 |
|---|---|
| author | Iman Khan Ahmed A. Elsanousi Amena M. Shareef Sameer S. Tebha Aabiya Arif Sana Gul |
| author_facet | Iman Khan Ahmed A. Elsanousi Amena M. Shareef Sameer S. Tebha Aabiya Arif Sana Gul |
| author_sort | Iman Khan |
| collection | DOAJ |
| description | Abstract Background: After introducing Covid‐19 vaccines, a few side effects were reported, pityriasis rosea being one of them. Therefore, this study will systematically review its manifestation afteradministration.Methods: Databases were searched, covering a timeline from December 1, 2019 to February 28, 2022. Data were independently extracted and accessed for bias. SPSS statistical software version 25 was used for appropriate inferential statistics. Results: Thirty‐one studies were included for data extraction after screening following the eligibility criteria. A total of 111 people were identified to have developed pityriasis rosea or pityriasis rosea‐like eruptions after vaccination, out of which 36 (55.38%) were female. The average age of incidence was calculated to be 44.92 years, and 63 (62.37%) people presented after administration of the first dose. It was found popularly in the trunk area, either asymptomatically or with mild symptoms. Meantime the onset, was 8.58 days, and meantime it took to recover, was 6.44 weeks. Conclusion: The association between pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccines was established, but given the scarcity of studies, there is a need to conduct different clinical trials to confirm this association further and study the etiology and mechanism of the disease. |
| format | Article |
| id | doaj-art-b9c83622e9ee4bb38f7b15fe134e00f7 |
| institution | DOAJ |
| issn | 2050-4527 |
| language | English |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-b9c83622e9ee4bb38f7b15fe134e00f72025-08-20T03:08:21ZengWileyImmunity, Inflammation and Disease2050-45272023-04-01114n/an/a10.1002/iid3.804Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic reviewIman Khan0Ahmed A. Elsanousi1Amena M. Shareef2Sameer S. Tebha3Aabiya Arif4Sana Gul5Department of Medicine Ziauddin Medical University Karachi Sindh PakistanDepartment of Medicine University of Medical Science and Technology Khartoum SudanDepartment of Medicine Deccan College of Medical Sciences Hyderabad IndiaDepartment of Neurosurgery and Neurology Jinnah Medical and Dental College Karachi Sindh PakistanDepartment of Medicine Ziauddin Medical University Karachi Sindh PakistanDepartment of Dermatology Jinnah Medical and Dental College Karachi Sindh PakistanAbstract Background: After introducing Covid‐19 vaccines, a few side effects were reported, pityriasis rosea being one of them. Therefore, this study will systematically review its manifestation afteradministration.Methods: Databases were searched, covering a timeline from December 1, 2019 to February 28, 2022. Data were independently extracted and accessed for bias. SPSS statistical software version 25 was used for appropriate inferential statistics. Results: Thirty‐one studies were included for data extraction after screening following the eligibility criteria. A total of 111 people were identified to have developed pityriasis rosea or pityriasis rosea‐like eruptions after vaccination, out of which 36 (55.38%) were female. The average age of incidence was calculated to be 44.92 years, and 63 (62.37%) people presented after administration of the first dose. It was found popularly in the trunk area, either asymptomatically or with mild symptoms. Meantime the onset, was 8.58 days, and meantime it took to recover, was 6.44 weeks. Conclusion: The association between pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccines was established, but given the scarcity of studies, there is a need to conduct different clinical trials to confirm this association further and study the etiology and mechanism of the disease.https://doi.org/10.1002/iid3.804cutaneous side‐effectsinfectionpapulosquamousSARS‐CoV‐2 vaccineskin diseasesvaccine hesitancy |
| spellingShingle | Iman Khan Ahmed A. Elsanousi Amena M. Shareef Sameer S. Tebha Aabiya Arif Sana Gul Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review Immunity, Inflammation and Disease cutaneous side‐effects infection papulosquamous SARS‐CoV‐2 vaccine skin diseases vaccine hesitancy |
| title | Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review |
| title_full | Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review |
| title_fullStr | Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review |
| title_full_unstemmed | Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review |
| title_short | Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review |
| title_sort | manifestation of pityriasis rosea and pityriasis rosea like eruptions after covid 19 vaccine a systematic review |
| topic | cutaneous side‐effects infection papulosquamous SARS‐CoV‐2 vaccine skin diseases vaccine hesitancy |
| url | https://doi.org/10.1002/iid3.804 |
| work_keys_str_mv | AT imankhan manifestationofpityriasisroseaandpityriasisrosealikeeruptionsaftercovid19vaccineasystematicreview AT ahmedaelsanousi manifestationofpityriasisroseaandpityriasisrosealikeeruptionsaftercovid19vaccineasystematicreview AT amenamshareef manifestationofpityriasisroseaandpityriasisrosealikeeruptionsaftercovid19vaccineasystematicreview AT sameerstebha manifestationofpityriasisroseaandpityriasisrosealikeeruptionsaftercovid19vaccineasystematicreview AT aabiyaarif manifestationofpityriasisroseaandpityriasisrosealikeeruptionsaftercovid19vaccineasystematicreview AT sanagul manifestationofpityriasisroseaandpityriasisrosealikeeruptionsaftercovid19vaccineasystematicreview |